Transthyretin Amyloid Cardiomyopathy Market 2024 Size, Global Report till 2031 | Ionis Pharmaceuticals, BridgeBio Pharma.

Transthyretin amyloid cardiomyopathy is a potentially fatal and often underdiagnosed disease characterized by the accumulation of amyloid protein fibrils in the walls of the left ventricle, the primary pumping chamber of the heart. In this condition, the amyloid protein is derived from transthyretin, a liver-produced transport protein responsible for carrying thyroxine (a thyroid hormone) and retinol (vitamin A) to various parts of the body. The deposition of amyloid protein fibrils in the heart walls leads to stiffness, impairing the left ventricle's ability to relax and fill with blood adequately, thus compromising its ability to effectively pump blood out of the heart. This dysfunction can result from genetic mutations or the natural aging process, which cause transthyretin to assemble abnormally, forming amyloid fibrils that travel through the bloodstream and deposit in various organs, including the heart. As these fibrils accumulate and thicken the heart tissue, they contribute to the development of cardiomyopathy and, ultimately, heart failure.

The growth of the transthyretin amyloid cardiomyopathy market is driven by several factors, including the increasing geriatric population, growing public awareness of the disease, the introduction of new drugs, and supportive government initiatives.

Click Here to Get Sample Copy of Transthyretin Amyloid Cardiomyopathy MarketReport :-
https://www.datamintelligence.com/download-sample/transthyretin-amyloid-cardiomyopathy-market

Market Dynamics :

The geriatric population is particularly susceptible to transthyretin amyloid cardiomyopathy due to the abnormal aggregation of transthyretin in elderly individuals. This condition, often unrecognized, presents as a significant cause of heart failure among older adults, stemming from the deposition of misfolded transthyretin or pre-albumin in the myocardium.

According to a 2021 report from the World Health Organization, the global population aged 60 years and older is projected to reach 1.4 billion by 2030, and this figure is expected to double to 2.1 billion by 2050. Additionally, the number of individuals aged 80 years and older is anticipated to triple by 2050, reaching 426 million. Aging is a primary risk factor for the development of this disease, with approximately 25% of individuals over 80 years old exhibiting significant transthyretin amyloid deposits in the myocardium, as reported by the American College of Cardiology.

Furthermore, the market for transthyretin amyloid cardiomyopathy is propelled by the launch of new drugs and favorable government initiatives. For instance, in January 2022, Eplontersen received Orphan Drug Designation in the US for the treatment of transthyretin amyloidosis. This designation, granted by the FDA, provides incentives for the development of medicines intended to treat rare diseases affecting fewer than 200,000 individuals in the US. Additionally, an increase in the launch of drugs targeting transthyretin amyloid cardiomyopathy during the forecast period is expected to contribute to market growth.

Get Customization in the report as per your requierments: https://www.datamintelligence.com/customize/transthyretin-amyloid-cardiomyopathy-market

Market Segmentation :

By Treatment Type : Heart Transplantation, Liver Transplantation.

By Medication Type : Tafamidis meglumine, Tafamidis, RNAi therapy, Diuretics, Beta-blockers, Digoxin.

By End-User : Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Access full Report Description - https://www.datamintelligence.com/research-report/transthyretin-amyloid-cardiomyopathy-market

Competitive Landscape

Pfizer Inc., Ionis Pharmaceuticals, BridgeBio Pharma, Alnylam Pharmaceuticals, Prothena Corporation, Regeneron Pharmaceuticals, Corino Therapeutics, Arcturus Therapeutics and Proclara Biosciences. Pfizer Inc.

Related Reports :-

Meningitis Vaccines Market : https://www.datamintelligence.com/research-report/meningitis-vaccines-market

DTaP Vaccine Market : https://www.datamintelligence.com/research-report/dtap-vaccine-market

Company Name: DataM Intelligence
Contact Person: Sai.K
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website:https://www.datamintelligence.com/

DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We at DataM Intelligence leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of Syndicate Reports & and; Customized Reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.